Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:04 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1245
Shown on this page
12
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Yale, New Haven, CT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1201–1212 of 1,245 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1Phase 2 Interventional

BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)

NCT02805023
Site status not listed — check the official record
View directory record Official record
Conditions
Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions
BGC101 (autologous EnEPC preparation), Control medium
Biological
Lead sponsor
BioGenCell Ltd.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
San Francisco, California • New Haven, Connecticut • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Nov 3, 2026, 6:04 PM EST
Active, not recruiting Not applicable Interventional

Study of the Relay Pro® Thoracic Stent-Graft in Subjects With Traumatic Injury of the Descending Thoracic Aorta

NCT03090230
Site status not listed — check the official record
View directory record Official record
Conditions
Other Specified Injury of Thoracic Aorta
Interventions
Relay Pro Thoracic Stent-Graft System
Device
Lead sponsor
Bolton Medical
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
16
States / cities
Irvine, California • Stanford, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Nov 3, 2026, 6:04 PM EST
Active, not recruiting Phase 1 Interventional

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
Livmoniplimab, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Nov 3, 2026, 6:04 PM EST
Recruiting Not applicable Interventional

The Dragon PLC Trial (DRAGON-PLC)

NCT06914648
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Primary Liver Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
Interventions
Portal Vein Embolization, Hepatic Vein Embolization
Procedure
Lead sponsor
Maastricht University
Other
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
5
States / cities
New Haven, Connecticut • Chicago, Illinois • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Nov 3, 2026, 6:04 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation

NCT03475212
Site status not listed — check the official record
View directory record Official record
Conditions
Cytomegalovirus Infections, Adenovirus Infection, EBV Infection
Interventions
Virus Specific T-cell (VST) infusion
Biological
Lead sponsor
Pediatric Transplantation & Cellular Therapy Consortium
Other
Eligibility
Not listed
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
30
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Nov 3, 2026, 6:04 PM EST
Active, not recruiting Phase 2Phase 3 Interventional Results available

Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery

NCT04068103
Site status not listed — check the official record
View directory record Official record
Conditions
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
Interventions
Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Patient Observation
Drug · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
932
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 639 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Nov 3, 2026, 6:04 PM EST
Active, not recruiting Not applicable Interventional

Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD

NCT04591392
Site status not listed — check the official record
View directory record Official record
Conditions
Heart Septal Defect, Heart Septal Defects, Atrial, Heart Defects, Congenital, Cardiovascular Abnormalities, Cardiovascular Diseases, Heart Diseases, Congenital Abnormalities
Interventions
reSept ASD Occluder
Device
Lead sponsor
atHeart Medical
Industry
Eligibility
Up to 84 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Thousand Oaks, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Nov 3, 2026, 6:04 PM EST
Recruiting Phase 2 Interventional

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

NCT03509961
Status at this site: Recruiting
View directory record Official record
Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen
Diagnostic Test · Drug
Lead sponsor
Pediatric Transplantation & Cellular Therapy Consortium
Other
Eligibility
1 Year to 25 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Nov 3, 2026, 6:04 PM EST
Recruiting Not applicable Interventional

Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension

NCT05884190
Status at this site: Recruiting
View directory record Official record
Conditions
Postpartum Hypertension
Interventions
Remote Medical Model (RMM), Community Health Model (CHM), SoC
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
6,030 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
New Haven, Connecticut • Worcester, Massachusetts • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Nov 3, 2026, 6:04 PM EST
Active, not recruiting Phase 2 Interventional

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

NCT04976634
Site status not listed — check the official record
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
Pembrolizumab, Belzutifan, Lenvatinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
16
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Nov 3, 2026, 6:04 PM EST
Active, not recruiting Phase 3 Interventional Results available

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

NCT04164901
Site status not listed — check the official record
View directory record Official record
Conditions
Grade 2 Glioma, Residual Glioma, Recurrent Glioma
Interventions
Vorasidenib, Matching Placebo
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
12 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
40
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Nov 3, 2026, 6:04 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk

NCT05576350
Status at this site: Recruiting
View directory record Official record
Conditions
Risk Behavior, Alcohol Use Disorder, HIV Infections
Interventions
Smartphone Based Alcohol Monitoring (SAM), Tracking and Reducing Alcohol Consumption (TRAC), TRAC-ER
Behavioral
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 35 Years
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
2
States / cities
New Haven, Connecticut • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 3, 2026, 6:04 PM EST

About this Yale institution page

What this page lists
ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Yale University at any site, browse by condition, or browse by U.S. city.